GLP-1 agonists -- which include blockbusters such as semaglutide (Rybelsus, Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) -- were initially approved for type 2 diabetes before gaining ...

Share on Twitter Print Share by Email Share Back to top In spring 2025, the Food and Drug Administration (FDA) resolved and ended the ...

Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings of ...